News und Analysen
Premier Inc. to Participate in the 39th Annual J.P. Morgan Virtual Healthcare Conference on January 12, 2021
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, announced today that members of its management team are scheduled to participate in a presentation and fireside chat at the 39
Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US and Develop National Surveillance Infrastructure
Illumina, Inc. (Nasdaq: ILMN) and Helix today announced a collaboration to augment national surveillance infrastructure in the US to track the emergence and prevalence of novel strains of
Hanger to Present at the 39th Annual J.P. Morgan Healthcare Conference
Hanger, Inc. (NYSE: HNGR), a leading provider of orthotic and prosthetic patient care services and solutions, announced today that members of its management team will participate in presentations
Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of
Pfizer Invites Public to Listen to Two Webcasts of Pfizer Discussions at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to two webcasts of discussions with Pfizer leadership at the 39th Annual J.P. Morgan Healthcare Conference to be held
Dexcom to Present at 39th Annual J.P. Morgan Healthcare Conference
DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 39th annual J.P. Morgan Healthcare
Simulations Plus Enters New Funded Collaboration to Enhance Top-Rated GastroPlus® ACAT™ Model for Oral Absorption of Peptides
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it
Sangamo Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on
Deciphera Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday
Sensorion Provides an Update on Plans and Progress in the Development of SENS-401 for the Prevention of Hearing Loss
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Puma Biotechnology to Present at the H.C. Wainwright VIRTUAL BioConnect Conference
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of
NanoString to Present at the 39th Annual J.P. Morgan Healthcare Conference
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that the company’s management is scheduled to present
Simulations Plus Sets Date for First Quarter Fiscal Year 2021 Earnings Release and Conference Call
Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report its financial results for the first quarter of fiscal year 2021, ended November 30, 2020, after the close of the financial
Charles River Laboratories Acquires Distributed Bio
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it acquired of Distributed Bio, Inc. on December 31, 2020. The acquisition marks the culmination of an exclusive
IMV to Participate in Two Upcoming Investor Events
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious
US FDA Accepts Regulatory Submission from Pfizer and OPKO for Review of Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency
Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the US Food and Drug Administration (FDA) has accepted for filing the initial Biologics License Application (BLA) for
Acadia Healthcare Announces Definitive Agreement to Sell U.K. Operations
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) (“Acadia” or the “Company”) today announced that it has entered into a definitive agreement to sell its U.K. operations to Waterland Private Equity
Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY®
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they will supply an additional 100 million doses of COMIRNATY®, the companies’ COVID-19 Vaccine, to the 27 European Union (EU)
Clovis Oncology Submits Investigational New Drug Applications for Novel Peptide-Targeted Radionuclide FAP-2286 for Therapeutic and Imaging Clinical Trial
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the company has completed submission of two Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA) for
Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis with MydCombi Targeting 80 Million Patient Encounters in the U.S. Annually
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company with Phase 3 programs in presbyopia, myopia and mydriasis, today announced that it has submitted a New Drug
LORBRENA® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer Accepted for Priority Review by U.S. FDA
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for LORBRENA ® (lorlatinib) as
THERANEXUS ANNOUNCES ITS FINANCIAL CALENDAR FOR 2021
Lyon, December 28, 2020 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction
Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
IMV Reports Update on COVID-19 Vaccine Program
IMV Inc. (Nasdaq: IMV; TSX: IMV) (the “Company”), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today
Lysogene Reports Positive Biomarker Data With LYS-SAF302
Regulatory News:
Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today reports positive biomarker data from the